CRISPR/Cas9 technology generated a glutamine to X change at amino acid 394 (Q394X) in exon 10. This corresponds to the Q388X mutation seen in some sporadic amyotrophic lateral sclerosis patients. Western blot analysis indicates that protein levels are reduced about 20% in the brain and spinal cord of homozygotes.